Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
HARNESSING AN ENDOGENOUS MECHANISM TO DELIVER siRNA TO THE KIDNEY
We have discovered a novel approach to create and deliver oligonucleotide medicines to the kidney, an organ that has historically been undruggable for genetic medicines. Judo Bio’s initial drug programs enable receptor-mediated uptake of oligonucleotides to specific kidney cell types using our proprietary ligand-siRNA conjugates, resulting in gene silencing of disease-modifying target genes.
Leveraging Renal Recycling
Receptor Physiology
to Treat Systemic and Kidney Diseases
The kidney is a complex organ, containing dozens of unique and specialized cell types.
The nephron is the functional unit of the kidney, composed of the glomerulus for filtration, tubules for reabsorption of water and solutes, and collecting ducts for electrolyte and fluid rebalance.
Most solutes, along with water, are actively reabsorbed in the proximal tubules of the kidney. Examples of solutes include albumin, immunoglobulins, hormones, nutrients, vitamins, minerals, amino acids, and metabolites.
Recycling receptors are expressed within cells in the nephron and provide access points for cell-specific delivery of therapeutics for the treatment of systemic and kidney diseases.
Learn more about
our platform FOR
DELIVERING siRNA TO
SPECIFIC KIDNEY CELL TYPES
We have rapidly built a pipeline of
MEGALIN-STRIKERS TO TARGET SOLUTE CARRIER PROTEINS
We are a team of
EXPERT DRUG DEVELOPERS
WITH DEEP KNOWLEDGE
OF RNA THERAPIES
